NASHVILLE, Tenn., May 20 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Commercial Officer Martin E. Cearnal will present a corporate overview at the Jefferies Global Life Sciences Conference in New York at 11:30 a.m. Eastern Time on Tuesday, June 8, 2010.
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast a replay will also be available on the Company website.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients.
For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.
SOURCE Cumberland Pharmaceuticals Inc.
Advertisement
The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section on Cumberland Pharmaceuticals' website at www.cumberlandpharma.com. Shortly following the live webcast a replay will also be available on the Company website.
Advertisement
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription laxative. The Company also recently launched Caldolor®, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients.
For more information on Cumberland Pharmaceuticals, please visit the Company website at www.cumberlandpharma.com.
SOURCE Cumberland Pharmaceuticals Inc.
